Pertuzumab HER2 inhibitors

Description Results NMA

OS 0.68 [0.56; 0.83]

PFS 0.62 [0.51; 0.75]

pertuzumab plus trastuzumab plus docetaxel (n=406)

vs.

placebo plus trastuzumab plus docetaxel (n=402)

double-blind

Parallel groups

Sample size: 406/402

Primary endpoint: progression-free survival

FU duration:

pertuzumab and trastuzumab plus docetaxel (n=107)

vs.

trastuzumab plus docetaxel (n=107)

4 arms: A) trastuzumab plus docetaxel; B) pertuzumab and trastuzumab plus docetaxel C)pertuzumab and trastuzumab D) pertuzumab plus docetaxel

Sample size: 107/107

Primary endpoint:

FU duration:

(n=4805)

vs.

(n=0)

double-blind

Parallel groups

Sample size: 4805/0

Primary endpoint: iDFS

FU duration: